APPROVABLE LETTERS IN THE FDA NEW DRUG APPROVAL PROCESS

被引：0

|

作者：

RICHARD, BW

ULCICKAS, M

LASAGNA, L

机构：

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1989年 / 29卷 / 08期

关键词：

D O I：

10.1002/j.1552-4604.1989.tb03402.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：680 / 684

页数：5

相关论文

共 50 条

[41] FDA may nix the "not approvable" letter
Fodor, K
SCIENTIST, 2004, 18 (17): : 47 - 47
[42] THE NEW DRUG APPROVAL PROCESS - CHANGES AND IMPACTS
PESKOE, MP
FOOD AND DRUG LAW JOURNAL, 1986, 41 (02): : 195 - 200
[43] NEW DRUG APPROVAL PROCESS UNDER SCRUTINY
ROSS, C
LANCET, 1994, 344 (8929): : 1075 - 1076
[44] FDAMA implementation policies to spur drug development, streamline FDA approval process
Wechsler, J
FORMULARY, 1999, 34 (02) : 176 - 177
[45] IMPACT OF FDA EXPEDITED REVIEW PROGRAMS ON NEW DRUG APPROVAL TIME
Ronnebaum, S.
Smith, D.
Andrawes, M.
VALUE IN HEALTH, 2024, 27 (06) : S7 - S7
[46] FDA drug approval: Chemistry review of new drug application, abbreviated new drug application, and botanical drug products
Getahun, Zelleka
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[47] A COMPARISON OF THE UNITED STATES' FDA APPROVAL PROCESS AND EUROPEAN EMA APPROVAL PROCESS
Fletes, F. J.
Kwak, E.
Vanet, J.
EUROPEAN PSYCHIATRY, 2013, 28
[48] FDA FINALLY SAYS MBIS ALBUNEX IS APPROVABLE
GINSBERG, M
BIO-TECHNOLOGY, 1994, 12 (07): : 656 - 657
[49] Approvable Letters in 2007 and the Outlook for 2008
Senak, Mark
AMERICAN HEALTH AND DRUG BENEFITS, 2008, 1 (01): : 41 - 42
[50] FDA shortened drug approval time in 1995
不详
PUBLIC HEALTH REPORTS, 1996, 111 (04) : 290 - 290

← 1 2 3 4 5 →